Peripheral T-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Peripheral T-Cell Lymphoma

MalaCards integrated aliases for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 12 73 20 15 37 70
Peripheral T Cell Lymphoma 36
Lymphoma T-Cell Peripheral 54


External Ids:

Disease Ontology 12 DOID:0050749
KEGG 36 H01892
ICD10 32 C84.4
UMLS 70 C0079774

Summaries for Peripheral T-Cell Lymphoma

KEGG : 36 Peripheral T cell lymphomas (PTCLs) are a group of rare lymphomas originating from mature (i.e., post-thymic or "peripheral") T lymphocytes and NK cells. With regard to the current WHO classification, leukemic, cutaneous, nodal, and extranodal PTCL are distinguished. The most common subtypes worldwide are the nodal T cell lymphomas. In the nodal T cell lymphomas, the major subtypes are PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and ALK-negative ALCL. Novel approaches are gradually clarifying the molecular pathogenesis of PTCLs. ALK gene translocation and dual specificity phosphatase 22 (DUSP22) gene translocation are seen in ALK-positive ALCL and ALK-negative ALCL, respectively. Recently, gene mutations in epigenetic regulators, including Ten-Eleven Translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), and isocitrate dehydrogenase 1 /2 (IDH1/2), are discovered in hematologic malignancies. The mutation frequencies were especially high in AITL and PTCL-NOS.

MalaCards based summary : Peripheral T-Cell Lymphoma, also known as peripheral t cell lymphoma, is related to angioimmunoblastic t-cell lymphoma and lymphoma, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TNFRSF8 (TNF Receptor Superfamily Member 8), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Akt Signaling. The drugs Thalidomide and Tyrosine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and thymus, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus.

Wikipedia : 73 Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the... more...

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)
# Related Disease Score Top Affiliating Genes
1 angioimmunoblastic t-cell lymphoma 32.4 TNFRSF8 TIA1 TET2 SYK MME GZMB
2 lymphoma 32.2 TNFRSF8 TIA1 TCL1A MS4A1 IL2 GZMB
3 anaplastic large cell lymphoma 32.0 TNFRSF8 TIA1 GZMB CXCR3 CCR4 ALK
4 lymphoma, non-hodgkin, familial 31.7 TNFRSF8 TCL1A SYK NCAM1 MS4A1 MME
5 adult t-cell leukemia 31.7 TNFRSF8 IL2 CCR4
6 t-cell lymphoblastic leukemia/lymphoma 31.7 TNFRSF8 TCL1A IL2RB IL2 CCR4
7 diffuse large b-cell lymphoma 31.6 TNFRSF8 SYK MME BCL6 ALK
8 t-cell lymphoma, subcutaneous panniculitis-like 31.6 TNFRSF8 TIA1 GZMB ALK
9 b-cell lymphoma 31.5 TNFRSF8 TIA1 TCL1A SYK MS4A1 MME
10 panniculitis 31.5 TNFRSF8 TIA1 NCAM1 GZMB CD8A
11 cutaneous t cell lymphoma 31.5 TNFRSF8 TIA1 IL2RB IL2 GZMB CXCR3
12 lymphoma, hodgkin, classic 31.5 TNFRSF8 TIA1 MS4A1 IL2 GZMB CCR4
13 alk-negative anaplastic large cell lymphoma 31.4 CXCR3 CCR4 ALK
14 alk-positive anaplastic large cell lymphoma 31.4 TNFRSF8 ALK
15 thrombocytopenia 31.4 TNFRSF8 SYK IL2 GZMB ETV6 CXCR3
16 hepatosplenic t-cell lymphoma 31.4 TIA1 GZMB
17 composite lymphoma 31.4 TNFRSF8 TIA1 MME GZMB BCL6
18 exanthem 31.3 SYK IL2 CD8A
19 follicular lymphoma 31.3 SYK MS4A1 MME BCL6
20 lymphoproliferative syndrome 31.3 TNFRSF8 TIA1 IL2 BCL6 ALK
21 mycosis fungoides 31.3 TNFRSF8 TIA1 NCAM1 IL2RB IL2 GZMB
22 marginal zone b-cell lymphoma 31.3 TNFRSF8 MME BCL6
23 lymphoblastic lymphoma 31.2 TNFRSF8 MME CD8A BCL6
24 t-cell adult acute lymphocytic leukemia 31.2 TNFRSF8 TIA1 IL2 CD8A CCR4 ALK
25 primary cutaneous t-cell lymphoma 31.2 TNFRSF8 MS4A1
26 lymphomatoid papulosis 31.1 TNFRSF8 TIA1 GZMB ALK
27 lethal midline granuloma 31.1 TNFRSF8 TIA1 NCAM1 GZMB
28 primary cutaneous anaplastic large cell lymphoma 31.0 TIA1 GZMB ALK
29 central nervous system lymphoma 31.0 IL2 CXCL13 BCL6
30 mature t-cell and nk-cell lymphoma 31.0 TNFRSF8 TIA1 TET2 NCAM1 MME IL2
31 pfeiffer syndrome 31.0 TNFRSF8 IL2 FGFR3 CD8A
32 mantle cell lymphoma 31.0 TCL1A SYK MS4A1 MME BCL6
33 b-cell non-hodgkin lymphoma 31.0 MS4A1 BCL6
34 lung lymphoma 30.9 TNFRSF8 MME BCL6
35 celiac disease 1 30.8 TIA1 NCAM1 IL2 GZMB CXCR3 CD8A
36 lymphosarcoma 30.8 TNFRSF8 BCL6
37 fasciitis 30.8 SYK IL2 ETV6
38 breast lymphoma 30.8 TNFRSF8 MME BCL6 ALK
39 seminoma 30.8 TNFRSF8 TCL1A NME1 FGFR3
40 leukemia, chronic lymphocytic 30.7 TNFRSF8 TCL1A SYK NCAM1 MS4A1 MME
41 allergic disease 30.7 TNFRSF8 SYK IL2 CXCR3
42 dermatitis 30.7 IL2RB IL2 GZMB CXCR3 CD8A CCR4
43 lymphomatoid granulomatosis 30.7 TIA1 GZMB
44 sarcoidosis 1 30.7 IL2RB IL2 CXCR3 CD8A
45 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.7 TNFRSF8 BCL6
46 hematologic cancer 30.7 TNFRSF8 SYK IL2 ETV6 ALK
47 myeloma, multiple 30.6 TET2 NCAM1 IL2 FGFR3 CD8A BCL6
48 parapsoriasis 30.6 TNFRSF8 CD8A
49 colon lymphoma 30.6 MME BCL6
50 follicular mucinosis 30.6 TNFRSF8 CD8A

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:

Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


GenomeRNAi Phenotypes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.8 NCAM1 SYK
2 Decreased viability GR00055-A-2 9.8 SYK
3 Decreased viability GR00221-A-1 9.8 ALK FGFR3 NME1 SYK
4 Decreased viability GR00221-A-2 9.8 FGFR3 NME1 SYK
5 Decreased viability GR00221-A-3 9.8 FGFR3 SYK
6 Decreased viability GR00221-A-4 9.8 ALK
7 Decreased viability GR00240-S-1 9.8 TIA1
8 Decreased viability GR00249-S 9.8 ALK FGFR3 GZMB NME1 SYK TIA1
9 Decreased viability GR00301-A 9.8 GZMB
10 Decreased viability GR00381-A-1 9.8 TIA1
11 Decreased viability GR00386-A-1 9.8 SYK
12 Decreased viability GR00402-S-2 9.8 CD8A CXCR3 IL2 NME1 SYK TCL1A

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 BCL6 CCR4 CD8A CXCL13 CXCR3 ETV6
2 cellular MP:0005384 10.14 BCL6 CD8A CXCL13 CXCR3 ETV6 FGFR3
3 immune system MP:0005387 10.13 BCL6 CCR4 CD8A CXCL13 CXCR3 ETV6
4 endocrine/exocrine gland MP:0005379 10.07 ALK BCL6 CD8A ETV6 IL2 IL2RB
5 mortality/aging MP:0010768 9.77 ALK BCL6 CD8A CXCR3 ETV6 FGFR3
6 liver/biliary system MP:0005370 9.76 BCL6 ETV6 IL2 IL2RB MME NME1
7 neoplasm MP:0002006 9.17 ALK CXCR3 ETV6 FGFR3 IL2 NME1

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
Apatinib Phase 4 811803-05-1
asparaginase Phase 4
5 Antibodies, Blocking Phase 4
Vinblastine Approved Phase 3 865-21-4 241903 13342
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
Aminopterin Investigational, Withdrawn Phase 3 54-62-6 2154
Cobalamin Experimental Phase 3 13408-78-1 6857388
16 Hematinics Phase 3
17 Adjuvants, Immunologic Phase 3
18 Analgesics Phase 3
19 10-deazaaminopterin Phase 3
20 Vitamin B12 Phase 3
21 Vitamin B 12 Phase 3
Adenosine Approved, Investigational Phase 2 58-61-7 60961
Mesna Approved, Investigational Phase 2 3375-50-6 598
Mogamulizumab Approved, Investigational Phase 2 1159266-37-1
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
Melphalan Approved Phase 2 148-82-3 4053 460612
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Palbociclib Approved, Investigational Phase 1, Phase 2 571190-30-2 5005498 5330286 11431660
Iron Approved Phase 2 7439-89-6 23925 29936
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381 214348
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
Busulfan Approved, Investigational Phase 2 55-98-1 2478
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693 40926
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166 2942
Vindesine Approved, Investigational Phase 1, Phase 2 59917-39-4, 53643-48-4 40839
Epirubicin Approved Phase 2 56420-45-2 41867
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
Daunorubicin Approved Phase 2 20830-81-3 30323
Daratumumab Approved Phase 2 945721-28-8
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1

Interventional clinical trials:

(show top 50) (show all 285)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Unknown status NCT03150602 Phase 4 Pralatrexate
2 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unknown status NCT03631862 Phase 4 Apatinib;CHOP Regimen
3 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
4 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
5 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma Recruiting NCT04040491 Phase 4 PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
6 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
7 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
8 Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP Completed NCT00970385 Phase 3 CHOP21;VIP/ABVD
9 A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT01482962 Phase 3 Alisertib;Pralatrexate;Gemcitabine;Romidepsin
10 A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT03349333 Phase 3 pralatrexate
11 A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas Completed NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
12 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
13 Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03952572 Phase 3 Cyclophosphamide;pegylated liposomal doxorubicin;Vincristine;Prednisone;Doxorubicin
14 Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Active, not recruiting NCT01796002 Phase 3 Romidepsin + CHOP;CHOP
15 A Randomized, Open-label, Active Controlled, Multi-center Phase 3 Clinical Study to Compare the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection With Chidamide in Patients With Relapsed/Refractory PTCL. Not yet recruiting NCT04668690 Phase 3 Mitoxantrone Hydrochloride Liposome Injection;Chidamide
16 Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Not yet recruiting NCT03553537 Phase 3 Decitabine;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
17 A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy Terminated NCT01420679 Phase 3 Pralatrexate Injection
18 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT04021082 Phase 2, Phase 3 Cerdulatinib
19 A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma Withdrawn NCT01355783 Phase 3 E7777
20 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT03355768 Phase 3 Romidepsin;Pralatrexate
21 A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Unknown status NCT00299351 Phase 2 Depsipeptide
22 A Multi-center, Prospective, Single-arm, Open Label Phase II Study of Chidamide Combined With Chemotherapy in the Treatment of Peripheral T Cell Lymphoma Unknown status NCT02753543 Phase 2 Chidamide
23 Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma: A Phase II Clinical Trial Unknown status NCT02856997 Phase 2 Chidamide with ICE regimen
24 A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Unknown status NCT03321890 Phase 2 Chidamide;prednisone;Cyclophosphamide;etoposide;Methotrexate
25 Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma, a Single-Center, Nonrandomized Phase II Clinical Trial Unknown status NCT02944812 Phase 2 Chidamide
26 Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II, Single-arm, Open-label, Muti-center Study Unknown status NCT02879526 Phase 2 C-CPT
27 The Efficacy and Safety Research of Endostar Combined With GDP to Treat Aggressive Peripheral T-cell Lymphoma (PTCL) in Phase II Clinical Study. Unknown status NCT02520219 Phase 2 GDP
28 The Efficacy and Toxicity of GDP Chemotherapy in Patients With Peripheral T-cell Lymphoma: An Open-label, Single-arm, Phase II Clinical Trial Unknown status NCT02404571 Phase 2 GDP chemotherapy
29 Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
30 Single-arm, Open and Multi-center Phase II Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Unknown status NCT03776279 Phase 2 Mitoxantrone Hydrochloride Liposome Injection
31 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
32 A Phase 2 Study Evaluating Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects Unknown status NCT03629873 Phase 2 Chidamide
33 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
34 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
35 Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65 Completed NCT00785330 Phase 2 standard GVHD prophylaxis;rituximab
36 A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies Completed NCT00038025 Phase 2 Deoxycoformycin (DCF)
37 Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001 Completed NCT01226472 Phase 2
38 A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT00364923 Phase 2 Pralatrexate Injection
39 A Pilot Phase II Study to Determine the Safety of the Combination of ONTAK (DAB389IL-2), an Interleukin-2 Fusion Toxin, in Combination With CHOP in Peripheral T-Cell Lymphoma Completed NCT00337987 Phase 2 Ontak;CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
40 A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma Completed NCT00136565 Phase 2 Velcade;Doxorubicin;Prednisone;Cyclophosphamide;Vindesine;Bleomycin
41 Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation Completed NCT01806337 Phase 2 Alemtuzumab
42 A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002) Completed NCT00426764 Phase 2 Romidepsin
43 Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients. Completed NCT01822886 Phase 2 Romidepsin + Gemcitabine
44 A Phase I/II Study of RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
45 A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL Completed NCT02106650 Phase 2 Folotyn and Leucovorin;Folic Acid;Vitamin B12
46 A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas Completed NCT01280526 Phase 1, Phase 2 Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP
47 Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects With Previously Treated Peripheral T-Cell Lymphoma Completed NCT00888927 Phase 1, Phase 2
48 A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT00865969 Phase 2 PXD101
49 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT02013362 Phase 1, Phase 2 Pralatrexate injection
50 A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Completed NCT02676778 Phase 2 E7777

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

MalaCards organs/tissues related to Peripheral T-Cell Lymphoma:

T Cells, Bone Marrow, Thymus, Skin, Nk Cells, Breast, Liver

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 2535)
# Title Authors PMID Year
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. 54 61
20217288 2010
Primary cutaneous follicular variant of peripheral T-cell lymphoma NOS. A report of two cases. 54 61
20459562 2010
Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. 61 54
19710685 2010
Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. 54 61
19377442 2009
[Small cell variant of peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic and immunophenotypic analysis]. 54 61
19575875 2009
[Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. 61 54
19575892 2009
Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. 61 54
19365529 2009
Chemokine receptor repertoire reflects mature T-cell lymphoproliferative disorder clinical presentation. 61 54
18842429 2009
[Peripheral T-cell lymphoma, NOS arising in Warthin tumor: report of a case]. 61 54
19031731 2008
Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. 61 54
18425045 2008
Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. 54 61
17582237 2007
Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. 54 61
17431414 2007
[Expression and clinical significance of Mcl-1 in T-cell non-Hodgkin's lymphoma]. 54 61
17430669 2007
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 54 61
17430665 2007
[Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma]. 61 54
17166378 2006
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 61 54
16680156 2006
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. 61 54
16341044 2006
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. 54 61
16091734 2005
Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. 61 54
16160469 2005
Peripheral T-cell lymphoma not otherwise specified vs. Hodgkin's lymphoma on fine needle aspiration cytology. 54 61
16124164 2005
Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. 61 54
15925824 2005
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. 61 54
15514005 2005
Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). 54 61
15965283 2005
Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. 54 61
15531460 2004
CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. 61 54
15328188 2004
Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. 54 61
15105810 2004
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 61 54
15133473 2004
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. 54 61
14616965 2003
Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. 61 54
12707037 2003
CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. 61 54
11979374 2002
T-cell receptor Vbeta repertoire in nodal non-anaplastic peripheral T-cell lymphomas. 54 61
12166895 2002
Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. 54 61
11731410 2001
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. 54 61
11222361 2001
Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. 61 54
11235901 2001
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. 54 61
10786666 2000
Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. 61 54
10414505 1999
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. 61 54
9736036 1998
Amplification of the TCL1 flanking region at 14q32.1 with no TCL1 gene transcription in a patient with peripheral T cell lymphoma. 54 61
9639427 1998
Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis. 54 61
8655683 1996
High-grade pleomorphic T cell lymphoma with restricted involvement of skin and bone marrow. 54 61
8513200 1993
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. 54 61
1373974 1992
[Midline malignant reticulosis: a histopathological, ultrastructural and immunohistochemical study of 11 cases]. 61 54
1813158 1991
Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. 61 54
1652981 1991
Low serum cholesterol levels predict inferior prognosis and improve prognostic index scoring for peripheral T-cell lymphoma, unspecified. 61
33631620 2021
Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan. 61
33167741 2021
Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma. 61
33787601 2021
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma With Secondary Cutaneous Involvement: A Diagnostic Challenge. 61
33264131 2021
Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma. 61
33576080 2021
Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma. 61
33320379 2021
Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. 61
33786592 2021

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

7 (show all 12)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

Pathways related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
5 12.08 IL2RB GZMB ETV6 BCL6
Show member pathways
9 11.72 MS4A1 MME CD8A
10 11.7 NCAM1 MS4A1 MME IL2RB IL2 CD8A
11 11.52 NCAM1 MS4A1 MME IL2 CD8A
Show member pathways
Show member pathways
11.19 IL2RB IL2 GZMB
Show member pathways
11.03 SYK IL2RB IL2

GO Terms for Peripheral T-Cell Lymphoma

Cellular components related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 MS4A1 MME IL2RB FGFR3 CXCR3 CD8A
2 cell surface GO:0009986 9.43 NCAM1 MS4A1 MME IL2RB FGFR3 CXCR3
3 external side of plasma membrane GO:0009897 9.1 NCAM1 MS4A1 IL2RB CXCR3 CD8A CCR4

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 IL2 CXCR3 CXCL13 CD8A CCR4
2 MAPK cascade GO:0000165 9.81 NCAM1 IL2RB IL2 FGFR3
3 cell chemotaxis GO:0060326 9.65 CXCR3 CXCL13 CCR4
4 positive regulation of kinase activity GO:0033674 9.61 IL2 FGFR3 ALK
5 chemokine-mediated signaling pathway GO:0070098 9.58 CXCR3 CXCL13 CCR4
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 IL2 CXCR3 CXCL13 CCR4
7 positive regulation of regulatory T cell differentiation GO:0045591 9.49 IL2 BCL6
8 negative regulation of B cell apoptotic process GO:0002903 9.37 IL2 BCL6
9 germinal center formation GO:0002467 9.32 CXCL13 BCL6
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.26 SYK FGFR3 CD8A ALK
11 leukocyte activation involved in immune response GO:0002366 9.16 SYK IL2
12 interleukin-2-mediated signaling pathway GO:0038110 8.8 SYK IL2RB IL2

Molecular functions related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TNFRSF8 TIA1 TET2 TCL1A SYK NME1
2 identical protein binding GO:0042802 9.23 TCL1A NME1 NCAM1 MS4A1 FGFR3 CXCR3

Sources for Peripheral T-Cell Lymphoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....